Zibotentan

齐波腾坦

Report date: 2025/08/19 20:00:08
NME

Base Information

Drug NameZibotentan
Drug Alias Namezibotentanum齐泊腾坦ZD-4054AZD-4054
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonists
TargetsEndothelin receptor type A
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursScleroderma, Limited +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[48] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenAstrazeneca Uk LtdAstrazeneca Plc
Inactive CompaniesCardiff UniversityUniversity College LondonUniversity Of Wisconsin-Madison +[8] 
Active IndicationsMicrovascular AnginaRenal Insufficiency, ChronicRenal Insufficiency +[5] 
Inactive IndicationsMetastatic breast cancerSolid tumoursScleroderma, Limited +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG